All In Biotech

Drug Trial Radar · NCT05767892

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Jul 30, 2025

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups YK-029A group or Platinum-based chemotherapy group. Participants will receive YK-029A orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.

Conditions

  • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • YK-209A tabletDrug

    YK-029A 200 milligram (mg) , orally without food,once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.

  • Pemetrexed+carboplatin/CisplatinDrug

    Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 .Time frame: Up to approximately 36 months after the first participant is randomized.

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, China

  • Peking University Cancer Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical Colleg

    Bengbu, Anhui, China

  • Anhui Provincial Chest Hospital

    Hefei, Anhui, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Yijishan Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Cancer Hospital Affiliated to Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    Guangzhou, Guangdong, China

  • People's Hospital of Zhongshan City

    Zhongshan, Guangdong, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • he First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhenzhou, Henan, China

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Third Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow Universit

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, China

  • Jilin Provincial Cancer Hospital

    Changchun, Jilin, China

  • he First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Cancer Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.